St. Lukes Hospital Of Duluth
- Type
- Teaching hospital
- Where
- Duluth, MN
- Medicare CCN
- 240047
- Received
- $399,394 in 77 records, 2020 ($8,983 general, $390,411 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: ST. LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Federal award recipient: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Nonprofit: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 12 | $8,983 |
| 2020 | Research payment | 65 | $390,411 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $311,135 | 2020 |
| Janssen Research & Development, LLC | 14 | $21,820 | 2020 |
| ABBVIE INC. | 13 | $16,174 | 2020 |
| Boston Scientific Corporation | 13 | $15,340 | 2020 |
| SANOFI PASTEUR INC. | 1 | $11,385 | 2020 |
| Abbott Laboratories | 5 | $5,600 | 2020 |
| CSL Behring | 10 | $5,419 | 2020 |
| Smith+Nephew, Inc. | 1 | $4,705 | 2020 |
| Eli Lilly and Company | 1 | $2,015 | 2020 |
| F. Hoffmann-La Roche AG | 2 | $1,371 | 2020 |
| Aesculap, Inc. | 2 | $1,144 | 2020 |
| Olympus America Inc. | 1 | $769 | 2020 |
| Merck Sharp & Dohme LLC | 2 | $750 | 2020 |
| PFIZER INC. | 1 | $600 | 2020 |
| Amgen Inc. | 1 | $600 | 2020 |
| LEICA MICROSYSTEMS INC. | 4 | $407 | 2020 |
| Linvatec Corporation | 1 | $158 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 65 | $390,411 |
| Gift | 7 | $6,256 |
| Space rental or facility fees (teaching hospital only) | 3 | $1,800 |
| Education | 1 | $769 |
| Grant | 1 | $158 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $12,600 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-12-10 | Aesculap, Inc. | $572 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $572 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-08 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-12-01 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-11-19 | CSL Behring | $450 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-19 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-11-16 | Boston Scientific Corporation | $377 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-11-05 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-10-28 | Abbott Laboratories | $200 | Research payment | Cash or cash equivalent | Optim Lead Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2020 |
| 2020-10-13 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-05 | Boston Scientific Corporation | $1,255 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-10-05 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-09-30 | ABBVIE INC. | $2,731 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-09-09 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | M14-064 | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $573 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-09-08 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-09-01 | F. Hoffmann-La Roche AG | $295 | Research payment | Cash or cash equivalent | Tarceva Drug, BioOncology | 1L NSCLC DX ALL COMER SQUAMOUS | 2020 |
| 2020-08-12 | Abbott Laboratories | $2,100 | Research payment | Cash or cash equivalent | Optim Lead Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2020 |
| 2020-08-11 | CSL Behring | $794 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-06 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-08-03 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-07-28 | ABBVIE INC. | $3,233 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-07-28 | CSL Behring | $712 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-20 | Boston Scientific Corporation | $1,045 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-07-06 | Boston Scientific Corporation | $347 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-06-22 | Boston Scientific Corporation | $3,380 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-06-22 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-06-22 | Janssen Research & Development, LLC | $130 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-06-18 | SANOFI PASTEUR INC. | $11,385 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-06-11 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-06-11 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-06-09 | F. Hoffmann-La Roche AG | $1,076 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | 1L NSCLC DX ALL COMER NON SQUAMOUS | 2020 |
| 2020-06-08 | Janssen Research & Development, LLC | $11,332 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-06-04 | Janssen Research & Development, LLC | $2,333 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-06-04 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Optim Lead Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2020 |
| 2020-05-28 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-27 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-05-06 | ABBVIE INC. | $480 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-04-30 | Smith+Nephew, Inc. | $4,705 | Gift | In-kind items and services | GRAFIX Biological, Other Advanced Wound Management | 2020 | |
| 2020-04-29 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Optim Lead Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2020 |
| 2020-04-28 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-27 | ABBVIE INC. | $2,731 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-04-26 | Olympus America Inc. | $769 | Education | In-kind items and services | UGN Glass & Metal Device, Urology/Gynecology | 2020 | |
| 2020-04-21 | Boston Scientific Corporation | $2,550 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-04-20 | Janssen Research & Development, LLC | $1,398 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-04-14 | Eli Lilly and Company | $2,015 | Research payment | Cash or cash equivalent | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECT | 2020 | |
| 2020-04-09 | CSL Behring | $267 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-08 | LEICA MICROSYSTEMS INC. | $195 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-04-06 | Boston Scientific Corporation | $728 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-03-24 | Merck Sharp & Dohme LLC | $250 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2020 |
| 2020-03-13 | LEICA MICROSYSTEMS INC. | $139 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-03-13 | LEICA MICROSYSTEMS INC. | $38 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-03-13 | LEICA MICROSYSTEMS INC. | $33 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-03-05 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2020 |
| 2020-03-04 | Linvatec Corporation | $158 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-03-02 | Boston Scientific Corporation | $3,190 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-02-28 | PFIZER INC. | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2020 | |
| 2020-02-19 | ABBVIE INC. | $1,659 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-02-18 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-02-18 | Boston Scientific Corporation | $422 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | INSIGHT ATP | 2020 |
| 2020-02-13 | CSL Behring | $794 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-13 | CSL Behring | $50 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-11 | AstraZeneca Pharmaceuticals LP | $83,841 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2020 |
| 2020-02-06 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-064 | 2020 | |
| 2020-02-05 | AstraZeneca Pharmaceuticals LP | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYMBICORT Drug, Respiratory | 2020 | |
| 2020-01-30 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-01-30 | Janssen Research & Development, LLC | $130 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-01-29 | Abbott Laboratories | $1,800 | Research payment | Cash or cash equivalent | Optim Lead Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2020 |
| 2020-01-27 | AstraZeneca Pharmaceuticals LP | $12,358 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2020 |
| 2020-01-27 | ABBVIE INC. | $1,659 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-465 | 2020 |
| 2020-01-23 | AstraZeneca Pharmaceuticals LP | $201,736 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2020 |
| 2020-01-23 | Janssen Research & Development, LLC | $2,097 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2020 | |
| 2020-01-21 | Boston Scientific Corporation | $470 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-01-13 | ABBVIE INC. | $180 | Research payment | Cash or cash equivalent | M14-064 | 2020 | |
| 2020-01-10 | Amgen Inc. | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-01-07 | CSL Behring | $350 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Duluth, MN, county St. Louis County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Duluth, MN | County St. Louis County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 87,093 | 200,123 | 5,739,445 |
| Population, 2020 census P1 | 86,697 | 200,231 | 5,706,494 |
| Median age B01002 | 35.2 | 41.2 | 38.8 |
| Under 18 B01001 | 17.6% | 18.6% | 22.9% |
| 65 and over B01001 | 17.3% | 21.4% | 17.3% |
| Households B11001 | 37,447 | 87,115 | 2,307,955 |
| Foreign born B05002 | 3.1% | 1.9% | 8.7% |
| Median household income B19013 | $68,807 | $70,069 | $89,062 |
| Median family income B19113 | $102,608 | $95,686 | $113,993 |
| Per capita income B19301 | $41,503 | $41,302 | $48,237 |
| Poverty rate B17001 | 16.8% | 13.2% | 9.3% |
| Unemployment rate B23025 | 4.7% | 4.6% | 4.1% |
| Civilian labor force B23025 | 48,580 | 102,280 | 3,119,042 |
| Mean commute (minutes) B08013 | 17.3 | 19.9 | 22.7 |
| Bachelor's degree or higher B15003 | 44.0% | 33.6% | 39.4% |
| Housing units B25001 | 39,978 | 104,263 | 2,545,030 |
| Owner-occupied B25003 | 59.4% | 71.2% | 72.2% |
| Renters B25003 | 40.6% | 28.8% | 27.8% |
| Median home value B25077 | $242,700 | $221,400 | $329,300 |
| Median gross rent B25064 | $1,087 | $1,013 | $1,280 |
| White, not Hispanic B03002 | 86.6% | 89.5% | 75.9% |
| Black B03002 | 2.7% | 1.6% | 6.9% |
| Hispanic or Latino B03002 | 2.6% | 1.9% | 6.4% |
| Asian B03002 | 1.7% | 1.0% | 5.1% |
| American Indian and Alaska Native B03002 | 1.3% | 1.5% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Duluth, MN.
Comments